CASE STUDY — Aventa Health and the Series C Breach
CASE STUDY — Aventa Health and the Series C Breach Domain: Cyber × Cloud × Org Design × Leadership × Strategy. The Corporate Background & Strategic Context Aventa Health sells the kind of story growth investors love: software that keeps chronically ill patients out of hospitals and shares the savings with the payers who'd otherwise foot the bill. The Decision Points & Debate Prompts 1. As the incoming CEO-equivalent decision-maker, identify which of the five pillars (Cloud, Cyber, Strategy, Leadership, Org Design) actually failed first, and propose the specific structural change that prevents recurrence — separation of duties, review gates, security headcount, a "no production PHI outside production" rule — and state honestly what that change costs in speed, in dollars, and in this competitive window. Built on the "unwatched gate" premise — an organization whose entire attention was pulled toward one campaign, leaving the perimeter undefended exactly when the raid arrived.
CASE STUDY — Aventa Health and the Series C Breach
Domain: Cyber × Cloud × Org Design × Leadership × Strategy. Built on the "unwatched gate" premise — an organization whose entire attention was pulled toward one campaign, leaving the perimeter undefended exactly when the raid arrived.
-
The Dilemma: Nine Days to Close, Seventy-Two Hours to Tell
-
The Corporate Background & Strategic Context
Aventa Health sells the kind of story growth investors love: software that keeps chronically ill patients out of hospitals and shares the savings with the payers who'd otherwise foot the bill. Its remote-monitoring platform watches roughly 1.2 million diabetic and cardiac patients across a dozen US health systems and a growing roster of self-insured employers, turning glucose readings and blood-pressure telemetry into nudges, escalations, and clinician alerts. The unit economics finally point the right way, and eight months ago the company planted a flag in Germany — its first move outside the US and now home to about 180,000 patients whose data sits squarely under GDPR.
But Aventa is a company that runs on the next round, not the last one. ARR is around $44 million; net burn is heavy enough that, absent new capital, the bank balance covers roughly five more months of payroll. Hanover Growth Partners has term-sheeted a $60 million Series C at a $420 million pre-money, with signing scheduled in nine days. The round is not a luxury. A better-capitalized competitor has started cloning Aventa's payer-contracting playbook, and the board has concluded that closing on time and at price is the difference between defending the category and being run down inside it.
Diligence has been brutal and total. For six weeks the entire company has pointed itself at one objective — get the round closed — and the org has bent around that gravity. Engineering has been racing a cloud migration meant to demonstrate "enterprise-grade" infrastructure to Hanover's technical advisors. Product built an investor-facing analytics dashboard to make the patient-growth and engagement numbers sing in real time. And Priya, the company's lone security engineer, was seconded weeks ago to assemble the SOC 2 evidence package and answer Hanover's security questionnaire — the very questionnaire that asserts Aventa's controls are sound.
That is the shape of the exposure, though no one has named it yet. Every defender marched off toward the raise. The thing they were defending — a warehouse of patient health records — was left at home with the gate open.
- The Incident: Systemic Collision & Breakdown
To make the dashboard convincing, a senior backend engineer needed production-shaped data and needed it fast. De-identifying the patient tables would have cost a sprint the calendar didn't have, so he replicated real production PHI — names, dates of birth, addresses, diagnoses, device telemetry — into a freshly provisioned cloud data warehouse spun up for the investor environment. To test it from his own laptop late one night, he widened the database's security-group rule to 0.0.0.0/0 on the database port, fully intending to tighten it in the morning. The replica also sat in a public subnet with a public IP, and authenticated with a service credential already committed to an internal config repo. The morning fix never happened; the ticket drowned under diligence requests. Normally Priya's review would have caught all three mistakes. Priya was buried in the security questionnaire.
For sixteen days the warehouse answered to the open internet. Automated scanners indexed the exposed port within the first day or two; some days later, an external actor connected and ran bulk queries against the patient tables, pulling them down wholesale. Aventa noticed only when a finance analyst flagged an unexplained spike in cloud egress charges — and, the same afternoon, a security researcher emailed the generic security alias to report an open database "that appears to contain medical data." Forensics, stood up overnight, confirmed the worst reading: bulk reads from a non-corporate IP, covering the full replica — approximately 1.2 million US patients and 180,000 EU data subjects.
The discovery lands on a Thursday, nine days before the Series C signing. Under GDPR, awareness has now occurred, and the 72-hour clock to notify the German supervisory authority is running. Under HIPAA, the 60-day individual-notification window has opened, and at least two partner health systems' BAAs demand notice within 24 to 72 hours of discovery. Inside the building, the mood curdles from exhausted to frightened in an afternoon. The dashboard the whole company sweated to build is now the instrument that exfiltrated its patients. And the signature page everyone has been racing toward contains warranties that, as of this Thursday, are no longer true.
- The Boardroom Collision
The founders convene the four people who have to be in the room. No one in this room is wrong.
The CTO (co-founder) — "We do this once, and we do it clean."
"I'm not going to give you a number on scope today because anyone who does is lying. We pulled the replica offline and we're imaging everything, but a real forensic timeline is days, not hours. Yes, that means the investor dashboard stays dark while we do it — I'm not leaving a compromised pipeline up so the numbers look pretty for Hanover. And let's be honest with ourselves about how we got here: I let security become one person, and then we borrowed that one person for the raise. If we paper over this to make the signing, we will be back in this room in six months with a worse version of the same meeting. I want to fix the system, not the optics."
The CFO — "Read the room and read the runway."
"Everything you're describing is correct and it might also kill the company. We have five months of cash. If we walk into Hanover today and say 'we've had a major patient-data breach,' the most likely outcomes are a re-price, a delay we can't survive, or a walk. And it's not only the round — our enterprise DPAs have breach clauses; some of those customers can terminate for cause the moment we notify them, and there go the engagement metrics the valuation rests on. I am not arguing for a cover-up. I'm telling you that 'disclose everything to everyone today' is itself a decision with body count, and we should make it with our eyes open, not because it feels clean."
The Chief Legal / Compliance Officer — "The clocks don't care how the round is going."
"Let me be precise about the exposure, because it's worse and stranger than it feels. The GDPR notification clock to the German authority is already running — seventy-two hours from this afternoon, and health data means we almost certainly owe individuals notice too. HIPAA gives us sixty days to patients and HHS, but our partner BAAs are tighter than that. Here's the part that should scare us most: we are private, so there's no SEC 8-K obligation — but Rule 10b-5 still reaches this financing. If we sign in nine days with reps that say 'no data breaches' and 'compliant with privacy laws,' knowing what we know today, that's not a late notification anymore, that's securities fraud, and it's personal for the officers who sign. And if we delay the regulators to protect the round, we hand OCR the willful-neglect tier on a plate — that's up to $2.19 million per violation, and the failures stack: the risk analysis, the access controls, the timeliness. Each one its own cap."
The VP of Product — "The team you need to fix this is the team you're about to break."
"I own the dashboard. I own the migration timeline. I'll carry that. But everyone keeps talking about 'standing up forensics' and 'a clean freeze' as if we have a fresh team to throw at it. We don't. These are the same eight people who've been doing diligence nights and weekends for six weeks. If we freeze everything and go dark on Hanover mid-diligence, we don't just blow the timeline — we tell the smartest people in our cap table that something's wrong, and they'll find out why. And the engineers who'd have to rebuild trust with our health-system customers afterward will be too burned out to do it. Whatever we choose, the constraint is human, and we are out of human."
-
The Decision Points & Debate Prompts
-
Sequence the impossible week. Design Aventa's first 72 hours as a single integrated plan that simultaneously (a) satisfies the GDPR notification clock and the partner BAA clocks, (b) preserves forensic integrity without leaving exploited infrastructure live, (c) addresses the Series C signing nine days out, and (d) keeps an exhausted eight-person team functional. Your plan must specify the order of regulator notice, investor disclosure, customer notice, and public disclosure — and defend why that order is least-bad. Where two obligations conflict in time, which one yields, and what is the price of yielding it?
-
Disclose-and-die vs. close-and-conceal. The CFO and the CLO are not disagreeing about facts; they're weighing a company that may not survive honest, timely disclosure against officers who may face fraud liability for closing atop a known breach. Take a position. If you disclose to Hanover before signing, how do you structure the conversation to maximize the odds the round survives re-priced rather than dead — and what do you concede? If you believe the round can ethically and legally proceed, specify exactly what must be true (disclosure, revised reps, indemnities, escrow) for the signature page not to become a fraud exhibit.
-
Name the real root cause — and price the fix. The proximate cause was a security-group rule; the systemic cause was an organization that pulled its only defender off the gate to chase a raise. As the incoming CEO-equivalent decision-maker, identify which of the five pillars (Cloud, Cyber, Strategy, Leadership, Org Design) actually failed first, and propose the specific structural change that prevents recurrence — separation of duties, review gates, security headcount, a "no production PHI outside production" rule — and state honestly what that change costs in speed, in dollars, and in this competitive window. If your fix would have made the dashboard impossible to ship in time, are you still willing to mandate it? Defend your answer to the board.
Discussion
- No comments yet, be the first to add one.